



July 17, 2014

## **NeuroMetrix, Inc. Announces Date for 2014 Second Quarter Financial Results Conference Call**

WALTHAM, Mass.--(BUSINESS WIRE)-- [NeuroMetrix, Inc.](#) (the "Company") (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today said it plans to issue its 2014 second quarter financial results before the opening of the market on July 24, 2014. The Company will host a conference call at 8:00 a.m., Eastern Daylight Time on July 24, 2014 to discuss its financial results as well as business developments affecting the Company.

The conference call may be accessed in the United States by dialing 877-415-3181 and using the confirmation code 36035520. Internationally, the conference call may be accessed by dialing 857-244-7324 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company's website at [www.NeuroMetrix.com](http://www.NeuroMetrix.com) under the "Investor Relations" tab.

A replay of the conference call will be available starting two hours after the call by dialing 888-286-8010, domestically and 617-801-6888, internationally. The confirmation code to access the replay is 86288051. The replay will be available for two weeks after the conference call.

### **About NeuroMetrix**

NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The Company has a major focus on diabetic neuropathies which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at \$14 billion in the United States. The Company markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with neuropathic pain such as painful diabetic neuropathy. The Company also markets the DPNCheck®, which is a rapid, accurate, and quantitative point-of-care test for peripheral neuropathies such as diabetic neuropathy. This product is used to detect neuropathies at an early stage and to guide treatment. For more information, please visit <http://www.NeuroMetrix.com>.

NeuroMetrix, Inc.  
Thomas T. Higgins, 781-314-2761  
SVP and Chief Financial Officer  
[neurometrix.ir@neurometrix.com](mailto:neurometrix.ir@neurometrix.com)

Source: NeuroMetrix, Inc.

News Provided by Acquire Media